Giulio Marchesini
Giulio Marchesini
Professor of Medicine, University of Bologna
Verified email at
TitleCited byYear
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
B Zinman, C Wanner, JM Lachin, D Fitchett, E Bluhmki, ...
New England Journal of Medicine 373 (22), 2117-2128, 2015
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
G Marchesini, E Bugianesi, G Forlani, F Cerrelli, M Lenzi, R Manini, ...
Hepatology 37 (4), 917-923, 2003
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome
G Marchesini, M Brizi, G Bianchi, S Tomassetti, E Bugianesi, M Lenzi, ...
Diabetes 50 (8), 1844-1850, 2001
Association of nonalcoholic fatty liver disease with insulin resistance
G Marchesini, M Brizi, AM Morselli-Labate, G Bianchi, E Bugianesi, ...
The American journal of medicine 107 (5), 450-455, 1999
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
P Angulo, JM Hui, G Marchesini, E Bugianesi, J George, GC Farrell, ...
Hepatology 45 (4), 846-854, 2007
Empagliflozin and progression of kidney dsease in type 2 diabetes
C Wanner, SE Inzucchi, JM Lachin, D Fitchett, M von Eynatten, ...
New england journal of medicine 375 (4), 323-334, 2016
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma
E Bugianesi, N Leone, E Vanni, G Marchesini, F Brunello, P Carucci, ...
Gastroenterology 123 (1), 134-140, 2002
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study
G Bedogni, L Miglioli, F Masutti, C Tiribelli, G Marchesini, S Bellentani
Hepatology 42 (1), 44-52, 2005
A position statement on NAFLD/NASH based on the EASL 2009 special conference
V Ratziu, S Bellentani, H Cortez-Pinto, C Day, G Marchesini
Journal of hepatology 53 (2), 372-384, 2010
Metformin in non-alcoholic steatohepatitis
G Marchesini, G Bianchi, S Tomassetti, M Zoli, N Melchionda
The Lancet 358 (9285), 893-894, 2001
Clinical features and natural history of nonalcoholic steatosis syndromes
Y Falck-Ytter, ZM Younossi, G Marchesini, AJ McCullough
Seminars in liver disease 21 (01), 017-026, 2001
Insulin resistance: a metabolic pathway to chronic liver disease
E Bugianesi, AJ McCullough, G Marchesini
Hepatology 42 (5), 987-1000, 2005
A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease
E Bugianesi, E Gentilcore, R Manini, S Natale, E Vanni, N Villanova, ...
The American journal of gastroenterology 100 (5), 1082, 2005
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
X Pi‑Sunyer, A Astrup, K Fujioka, F Greenway, A Halpern, M Krempf, ...
New England Journal of Medicine 373 (1), 11-22, 2015
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease
N Villanova, S Moscatiello, S Ramilli, E Bugianesi, D Magalotti, E Vanni, ...
Hepatology 42 (2), 473-480, 2005
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes
AL Fracanzani, L Valenti, E Bugianesi, M Andreoletti, A Colli, E Vanni, ...
Hepatology 48 (3), 792-798, 2008
A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon
G Fattovich, G Giustina, S Favarato, A Ruol, ...
Journal of Hepatology 24 (1), 38-47, 1996
Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial
G Marchesini, G Bianchi, M Merli, P Amodio, C Panella, C Loguercio, ...
Gastroenterology 124 (7), 1792-1801, 2003
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver
E Bugianesi, P Manzini, S D'Antico, E Vanni, F Longo, N Leone, ...
Hepatology 39 (1), 179-187, 2004
ESPEN guidelines for nutrition in liver disease and transplantation
M Plauth, M Merli, J Kondrup, A Weimann, P Ferenci, MJ Muller, ...
Clinical Nutrition 16 (2), 43-55, 1997
The system can't perform the operation now. Try again later.
Articles 1–20